354813-48-2

Upstream product

• 281235-04-9 methyl 4-(piperidine-4-yl)benzoate 
• 74-88-4 methyl iodide 
• 196204-01-0 4-(piperidin-4-yl)-benzoic acid 
• 286961-15-7 benzyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1 (2H)-pyridinecarboxylate 
• 586-76-5 4-Bromobenzoic acid 
• 50-00-0 formaldehyd 
• 771-99-3 4-phenylpiperidine 
• 1453272-47-3 ethyl 4-(piperidin-4-yl)benzoate hydrochloride 
• 180912-08-7 4-(4-bromophenyl)-1-methyl-1,2,3,6-tetrahydropyridine 
• 139474-25-2 4-(4-bromophenyl)-1-methylpiperidin-4-ol 
• 1445-73-4 1-Methyl-4-piperidone 
• 67-56-1 methanol 
• 79-37-8 oxalyl dichloride 
• 774-52-7 1-methyl-4-phenylpiperidine 

Downstream Products

• 354813-49-3 4-(1-methylpiperidin-4-yl)benzoic acid 
• 1035269-77-2 N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(1-methyl-4-piperidyl)benzamide 
• 1071756-46-1 C₁₃H₁₉NO 
• 1276024-93-1 (4-(1-methylpiperidin-4-yl)phenyl)carbaldehyde 

Relevant academic research and scientific papers

BENZO- AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS

The invention relates to new chemical compounds of Formula (I), pharmaceutical compositions containing them, and their use for the pharmacological treatment of a cancer, preferably a glioblastoma.

Pyrazolo [3,4 - the b] pyridine and [...] composition preparation method and use of (by machine translation)

The present invention provides a pyrazolo [3,4 - the b] pyridine and [...] compound of preparation and use, in particular, the present invention provides a following formula (I) compounds are shown, wherein the definition of each group as described in the specification. The compounds of the invention has excellent tyrosine kinase inhibiting activity, so can be used for preparing a series of treating diseases associated with the tyrosine kinase activity of the drug. (by machine translation)

AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES

Provided are amido spirocyclic amide and sulfonamide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

NOVEL INHIBITORS

The invention relates to novel pyrrolidine derivatives of formula (I): wherein R1, R2 and R3 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.

NOVEL COMPOUNDS

There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.

New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture

The present invention relates to carboxamide compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1, R2, R3 and k have the meanings given in claim 1. Moreover the invention relates to process for preparing the above mentioned carboxamides as well as pharmaceutical compositions containing at least one carboxamide according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.